How much is AgomAb worth in 2026?

AgomAb has a current valuation of $415.6M based on their Later Stage VC round and secondary market data.

How much funding has AgomAb raised?

AgomAb has raised $334.0M in total funding across 1 funding rounds.

AgomAb

Drug DiscoveryWebsite

AgomAb valuation and funding history | Last updated: October 25, 2024 | 1 funding rounds

Current Valuation

$415.6M

As of October 25, 2024

Total Funding Raised

$334.0M

Across 1 round

Last Round

Later Stage VC

$90.1M

Last Funding

Oct 2024

Funding date

Capital Efficiency

1.24x

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
October 11, 2023	Later Stage VC (Series C)	$100.7M	N/A	-

Valuation Analysis

Current Valuation Metrics

AgomAb is currently valued at $415.6M as of October 25, 2024. The company has raised a total of $334.0M in funding across 1 funding round.

Capital Efficiency

With a capital efficiency ratio of 1.24x, AgomAb has achieved a valuation that is 1.24 times the total capital raised.

Track AgomAb Valuation Updates

Get notified when AgomAb raises new funding or valuation changes

Explore More Data

Detailed analysis for AgomAb

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock AgomAb's valuation history, funding rounds, and growth metrics.

No credit card required

What is AgomAb Worth in 2026?

AgomAb is a leading private company in the Drug Discovery sector. Track AgomAb's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How AgomAb Valuation is Determined

Private company valuations like AgomAb's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.